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ABSTRACT
The term functionomics (Amin 2003, Neumann et al. 2004) refers to a postgenomic integrated Systems Biology
(Attur et al. 2002) using a multidimensional approach for cells, tissues and organs. It considers current or future
involvement among genomics, proteomics or metabolomics, including the main factors that cause biological responses
and modulation under different conditions. Our objective in the present review is to summarize the contemporary
understanding of functionomics of smooth muscle pharmacology, based on the results obtained on the pregenomic
era during several years in our laboratory. The present approach is based on the knowledge of the dynamics of the
receptor system, which comprises a cascade of phenomena, leading from the drug administration to the final biological
response. We will describe several conditions in which the final effect is modified, based on perturbations induced on
drug absorption, distribution, metabolism, interaction with receptors and mobilization of second messengers, as well
as by interactions with a second receptor system. We will also discuss the gaps that need to be fulfilled in order to
obtain a clear and better understanding of the receptor system in smooth muscle, and to narrow the bridge between our
knowledge of the function of biological systems, genomics, and other recently introduced areas.
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INTRODUCTION
Less than 10 years ago, the outstanding journal Science
published a number of reviews under the title “Whole-
istic Biology” (Chong and Ray 2002). This period is
being named as the postgenomic era (Amin 2003), when
a field named as Systems Biology was considered (Attur
et al. 2002), in which genes and other agents are taken
into account. The main goal was to verify how changes
to one part of a system may affect other parts (Kitano
2002, Davidson et al. 2002). With the rapid progress of
genomics, the emphasis has initially given rise to the sci-
ence of proteomics and metabolomics, namely the study
In commemoration of the 75th anniversary ofEscola Paulista de Medicina / Universidade Federal de São Paulo.*Member Academia Brasileira de CiênciasCorrespondence to: Dr. Aron JurkiewiczE-mail: aron.farm@epm.br
of all the proteins and its metabolism produced by cells
and organism, involving the identification of proteins and
biotransformations in the body. This was followed by
functionomics (Amin 2003, Neumann et al. 2004) with
attempts to fetch the corresponding functions.
A major challenge to be foreseen in functionomics
is the integration of proteomics with genomics and
metabolomics data, and mainly the integration with their
physiological and pathophysiological functional inter-
pretation, in conjunction with clinical results and epi-
demiology. To explore such a vast space, new forms to
exploit and link these fields with pharmacological data
will be essential to ask possibly new kinds of questions
about the complex nature of therapeutics. This integra-
tion is meant to follow different routes, either from the
gene to the function, or vice-versa.
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A number of technical obstacles remain before
functionomics can have strengthened its interpretation
in conjunction with routine genomics, proteomics and
metabolomics: (a) more than 40% of the 35,000 genes
(and possibly 120,000 different proteins they may code)
have not been ascribed any functional attribute, neither
a biochemical or cellular function nor a function at the
tissue/organism level (Attur et al. 2002); (b) on the other
hand, there is a large number of functions that still re-
main to be correlated with genes and proteins (Amin
2003); (c) when dealing with a gene-driven approach
and a phenotype-driven approach, it has to be considered
that in general the genetic information is static, while the
functional correlate is dynamic (Davidson et al. 2002).
One of the methods used to check for correlations
between the different parts of the receptor system cascade
(Fig. 1) is to introduce a perturbation in the biological
system and to track the steps which lead to the changes
observed on the final response. In our lab, various al-
terations have been detected in vas deferens after differ-
ent types of spontaneous or induced perturbations, such
as denervation, castration, transplantation, hypothermia,
aging, genetic hypertension, neurodegenerative diseases,
or the involvement of a second receptor system. These
points will be summarized below, in the light of the al-
leged receptor system cascade, as functional candidates
for the 40% of gene population whose function is still
unknown.
Fig. 1 – The receptor system cascade in smooth muscle, modified from
Ariens (1954).
THE RECEPTOR SYSTEMS IN SMOOTH MUSCLE
The initial functional studies on drug-receptor interac-
tion were mainly due to the pioneering publications of
Hill (1909) and Clark (1926, 1933), when the molecular
structure of receptors was still unknown. The structures
were still a matter of speculation when Ariens (1954,
1964) presented a Receptor Theory, based mainly on
the study of pharmacological receptors in muscle. The
receptor was depicted as part of a chain of events which
included phenomena preceding the interaction of drugs
with receptors (absorption, distribution, metabolism) as
well as following the formation of the drug-receptor
complex (stimulus) leading to the biological response.
The ability to form the stimulus was independently
named as intrinsic activity by Ariens (1954), or efficacy
by Stephenson (1956). Shortly after, attention was given
to the so-called intrinsic efficacy and to the biophase,
an organ compartment where receptors are supposed to
be located (Furchgott 1964, Furchgott and Bursztyn
1967, Furchgott et al. 1973). Furthermore, a new para-
meter, relative responsiveness, was presented to com-
pare receptor systems with each other (Jurkiewicz et al.
1969, 1976).
In the last decades of the previous century, the
Ariens’ so-called stimulus was already considered as
a transducing or signaling pathway, comprising second
messengers such as cyclic AMP (Sutherland 1972), G-
proteins (Hill 2006, Milligan and Kostenis 2006), and
some ions as calcium (Jurkiewicz et al. 1975, 1994b,
Castillo et al. 1992, Smaili et al. 1998, Verde et al.
2002, Lopes et al. 2006, 2007, Lafayette et al. 2008),
sodium (Belevych et al. 1999), or potassium (Harhun
et al. 2003). This picture was further improved thanks
to the development of new methods, such as receptor
binding with radioligands as for instance by Castillo et
al. (1992), and electrical identification of selective ion
channels (Belevych et al. 1999, Harhun et al. 2003).
At this point the receptor could still be depicted as a
cascade of phenomena, as suggested by Ariens, except
that the stimulus was replaced by the mobilization of
second messengers, as shown in Figure 1. An addi-
tional stimulating improvement was achieved thanks
to the development of genomics, leading to the identifi-
cation of genes expressing mainly receptors (Alexander
et al. 2008) and ion channels (Catterall et al. 2002). In-
formation was also collected about the duplicated func-
tions of receptors, namely in active or inactive states, as
well as about receptor phosphorilation, desensitization
and internalization (Hill 2006).
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Although a correlation has been shown between
genes, receptors and contraction in smooth muscle pre-
parations, as for instance by Jurkiewicz et al. (2006), a
more comprehensive picture is still missing concerning
the role of different steps on the receptor cascade, as well
as a dynamic overview of the influence of modulation,
considering that receptor systems are greatly influenced
by endogenous or external factors and can constantly
undergo changes.
In spite of the consensus among various investiga-
tors that a single genetic approach is not sufficient to
give a comprehensive picture of the receptor cascade, a
number of points remain less considered, and deserve a
more accurate analysis in order to pervade all the neces-
sary steps:
(a) the fact that the cascade for a given receptor is not
static, but can be modulated by various means,
(b) the need for more information about the strategies
for measuring changes on receptor functions,
(c) the presence of functions that are still looking for a
gene correlation, and
(d) the presence of a large number of results that have
not been compared in parallel and need to converge
to a structural, dynamic and systemic level.
MODULATION BY FACTORS INDUCING PERTURBATIONS
ON THE RECEPTOR SYSTEM
Not surprisingly, it is known that a pharmacological ef-
fect is triggered by a pharmacological receptor, which
is initially expressed by a gene; it is less known though
that receptor systems, as depicted in Figure 1, can be
altered and followed by means of perturbation analysis
(Davidson et al. 2002), in which the biological object
is modified experimentally or naturally, causing a paral-
lel alteration on the operation of several signaling pro-
cesses. In other words, the cascade of phenomena lead-
ing to the final biological response can be modulated,
resulting in various different final effects, although gen-
erated from the same gene. This article sketches at least
two underlying points that have been considered in our
experiments: (a) the agents or modulation factors induc-
ing perturbations, and (b) the resulting changes or func-
tional linkages of the final effect. These points will be
summarized below.
INNERVATION
The smooth muscle cells are part of organs or tissues
that in general are innervated by sympathetic or para-
sympathetic neurons. Some of our experiments were
performed by removing the influence of nerve tissue,
by means of organ denervation. We have shown that
surgical denervation causes a striking 30-fold increase
of the contractile responses induced by sympatomimetic
drugs on the rat vas deferens, because of the removal
of neuronal uptake (Jurkiewicz et al. 1991, 1992). This
experiment clearly shows how a phenomenon preceding
the drug-receptor interaction can modify the receptor-
induced function. It is noteworthy that this increase
is similar to that induced by cocaine in non-denervated
vas deferens (Jurkiewicz and Jurkiewicz 1976). A sec-
ond remarkable change caused by denervation is the
highly significant decrease of the density of plasmalemal
L-type voltage-dependent calcium channels, as shown
through radioligand binding studies (Jurkiewicz et al.
1994b). In addition, we have also shown that a down-
regulation occurs for various enzymes of sarcoplasmic
reticulum, such as calcium-magnesium ATP-ases in-
volved in cellular calcium homeostasis (Quintas et al.
2005). Similar decreases were observed for alfa 2 sub-
unit of sodium-potassium ATPases (Quintas et al. 2000,
2002). We have also described that the density of rian-
odine receptor in sarcosplasmic reticulum is decreased
by about 45% after denervation of the vas deferens.
Since calcium is one of the most important sec-
ond messengers for muscle contraction, including the
vas deferens (Jurkiewicz et al. 1975, 1994b), this de-
crease leads obligatorily to general functional changes
of drug effects.
HORMONES
Some organs and tissues are known to be hormone-de-
pendent. This is the case for the rat vas deferens, as
shown by the pioneering work of Martins and Valle
(1939) after castration of male rats and other animal
species. We have shown that, besides the well-known
morphological changes due to the decrease of circulat-
ing testosterone, several hormone-induced pharmacol-
ogical modifications might be related to modifications of
calcium translocation (Jurkiewicz et al. 1977b, Calixto
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et al. 1983, Aucelio et al. 1985), that can be unquestion-
ably ascribed to the striking decrease, of about 90%, of
the density of cell membrane calcium channels (Castillo
et al. 1992).
EPITHELIUM
Since the classical experiments of Furchgott showing
the function of epithelium as a source of nitric oxide
(Vladimirova et al. 1994), our interest has been directed
to the performance of experiments with epithelium-free
vas deferens (Jurkiewicz et al. 1994a, Caricati Neto et
al. 1995). As a matter of fact, an unexpected and dis-
tinctive result was obtained by Okpalaugo et al. (2002),
showing that just the effect of the alpha 2 agonist cloni-
dine was significantly increased after surgical excision
of the epithelium, while the effects of other adrenergic
and cholinergic drugs were not changed. It is still un-
known whether or not this effect is related to the influ-
ence of a still unidentified endogenous agent (Jurkiewicz
and Jurkiewicz 1992), that might have been removed
together with the epithelium.
GENETIC FACTORS
Hypertension is still one of the most unresolved
therapeutic problems. It is a consequence of functional
changes that involve not only the cardiovascular system,
but also other tissues and organs, as could be observed
for the vas deferens of the rat genetically modified SHR
(Spontaneously Hypertensive Rat). We have shown that
there is a significant increase of alpha-adrenoceptors in
this organ (Caricati Neto et al. 1992), a condition which
can be related to the increase of blood pressure due to the
involvement of arterial smooth muscle. More recently,
we have shown for the first time that catecholamine re-
lease has greater quantal content and faster kinetics in
isolated chromaffin cells of SHR, measured through sin-
gle vesicle amperometry (Miranda-Ferreira et al. 2008,
2009).
AGING
Due to increased human lifetime expectancy during the
recent decades, aging has become an important pharma-
cological issue. We have shown recently that several drug
functions are modified in smooth muscle of senescent
rats. For instance, calcium intracellular stores in sar-
coplasmic reticulum and mitochondria of rat colon are
changed in aged rats, affecting gastrointestinal smooth
muscle motility in response to cholinergic neurotrans-
mitters (Lopes et al. 2006). Studies were also made with
cholinergic agents in rat jejunum of aged rats, showing
a relation of these changes to an aging-modified calcium
translocation (Lopes et al. 2007).
It should be emphasized that the influence of age
can also be shown when studying newborn animals
(Csaba 1980). As a matter of fact, we have shown that
rat pups injected with the calcium channel blocker nife-
dipine presented an up-regulation of these channels in
rat vas deferens (Verde et al. 2002). In addition, in an-
other experimental approach, a reversible decrease of
responsiveness to serotonin and noradrenaline was de-
tected for pups that were breast-fed with the milk of
mothers injected daily with the serotonin neuronal up-
take blocker fluoxetine (Pereira et al. 2007). Since these
mothers were also injected during pregnancy, it is quite
possible that this treatment also influenced the pups
during fetal life.
HYPOTHERMIA
Low temperature is an important agent for organ preser-
vation ex vivo, mainly when considered for acute trans-
plantation. In some cases, the organs have to be main-
tained in special nutrient solutions under ischemic con-
ditions during several hours before transplantation. We
have shown that small bowel segments (usually jejunum)
presented autonomic dysfunctions when maintained un-
der these conditions. In general, there was a reduction
of the cholinergic function after up to 24 hours of hypo-
thermia, although some drugs as heparin, ascorbic acid,
and allopurinol attenuated the functional changes (Taha
et al. 2004a, b, 2006). This dysfunction might be due to
a partial degeneration of nerve tissue, which is known to
occur under hypothermia before the changes of muscle
cells take place (Jurkiewicz et al. 1992).
TRANSPLATATION
Several pharmacological and morphologic alterations
were observed when the vas deferens was transplanted
to the anterior wall of the cecum. (Jurkiewicz et al.
1977a). Besides a rapid denervation followed by a
slow re-innervation during the subsequent 30 days (Jur-
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kiewicz et al. 1991), we have clearly detected, in the ini-
tial days, a functional change in the balance between α1aand α1b adrenoceptor populations (Pupo and Jurkiewicz1997). This can be considered as a clear functional
demonstration of a change of two subtypes of α-adreno-
ceptors through this procedure.
NEURODEGENERATIVE DISEASES
We have studied a model for Huntington disease by
treating rats with 3-nitroproprionic acid, an inhibitor of
complex II of respiratory chain. This was followed by
measurements of apoptosis, calcium translocation and
behavior. It was suggested that these three effects might
be interrelated and may precede degenerative processes.
In other words, we have shown through this model that
these signaling agents were modified in a parallel fash-
ion, suggesting that a similar neurological abnormality
occurs in humans (Rosenstock et al. 2004).
INVOLVEMENT OF UNEXPECTED RECEPTOR SITES
In a study aimed to analyze the effect of a group of
cholinesterase blockers used for the treatment of Al-
zheimer’s disease, namely galantamine, tacrine, rivas-
tigmine and donepezil, we have observed that, besides
blocking the enzyme, these agents were also unexpect-
edly able to enhance the purinergic neurotransmission
in rat vas deferens (Caricati Neto et al. 2004). It was
also observed by Santos et al. (2002) that galantamine
causes an allosteric modification of nicotinic receptors.
It is still unknown whether or not these effects are in-
volved in the treatment of this disease. In other unre-
lated experiments we have observed that the endo-
genous agent agmatine induces a contractile effect in
the rat vas deferens whose receptor involved could not
be clearly identified, in spite of the use of a number of
receptor blockers (Jurkiewicz et al. 1996). In another
further publication, we have reported for the first time
that nitric oxide behaves as a second messenger for the
neurotransmission in rat vas deferens (Vladimirova et
al. 1994). Finally, in a recent study, we have verified
that the androgenic hormone testosterone interacts with
a non-genomic site whose nature is still unknown, induc-
ing a fast relaxation of the rat vas deferens, contrary to
the expectations for the well-known slow genomic mor-
phologic alteration (Lafayete et al. 2008).
PUTTING TOGHETHER GENOMICS AND FUNCTIONOMICS
We have studied the contractile responses of the rat tes-
ticular capsule (RTC), which is a thin tissue surround-
ing the testis, whose precise function is still unknown
(Jurkiewicz et al. 2006). Simultaneously, RT-PCR as-
says were also made. From the functional standpoint,
the adrenergic receptor (AR) subtypes were character-
ized through neurogenic contractions elicited by elec-
trical field stimulation (EFS), noradrenaline, or by the
blockade by antagonists of AR. In addition, the RT-PCR
assays were made to check for the expression of the
three presently known subtypes of α1-ARs. The effectsof EFS showed that the release of NA from sympathetic
nerves, contrary to ATP, was involved in contractions.
The α1-selective antagonist prazosin was more effec-tive than the α2-selective antagonist idazoxan to inhibitEFS-contractions, pointing out a major involvement of
α1-AR. The contractions by NA were competitivelyblocked by α1A- and α1B-, but not by α1D-selective ARantagonists. Interaction with α2-AR antagonists wasnegligible. Summarizing, the results on contraction show
the presence of functional α1A- and α1B-ARs, but not of
α2- and α1D-ARs in rat testicular capsule. In relation toRT-PCR assays, the presence of mRNA encoding α1A-and α1B-AR was also shown. One of the main, thoughunexpected findings was that a α1D-transcript was alsodetected in these assays, contrary to the functional re-
sults. Taken together, our results show that contractions
involve the interaction of NA with both α1A- and α1B-,but not with α1D- or α2-AR subtypes. It is surpris-ing that the α1D-AR subtype could not be detected bycontraction experiments, in spite of its presence as the
corresponding mRNA. It is suggested that the α1D-ARgene might be linked to another function that is unre-
lated to contraction.
LOOKING FOR GAPS BETWEEN GENOMICS
AND RECEPTOR FUNCTION
One of the main goals in functionomics is to find out
if and how changes of a final biological response oc-
cur in parallel with modifications of the corresponding
genes. The key difficulty resides in the fact that a com-
plex biological response, as for instance a contraction,
or a release of a neurotransmitter, or a hormonal se-
cretion, depends on a chain of events involving many
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genes. For instance, in the case of a drug-induced con-
traction, multiple genes can participate in steps such as
drug metabolism, release and synthesis of second mes-
sengers, crossing of ions through selective channels, and
others, as advanced in Figure 1. For instance, we have
described above that a contractile drug effect is modified
by organ denervation or transplantation due to block-
ade of neuronal uptake, or by animal castration due to
changes of the density of calcium voltage-dependent
channels, or by genetic factors, such as hypertension,
due to modifications of the adrenoceptor proper. An-
other example is the change of final biological response
when a down regulation occurs for ATPases of sarcoplas-
mic reticulum after denervation. Other changes were
also described above for aging and hypotermia, which
are still expecting for a clear correlation with the corre-
sponding genes, as well.
Furthermore, although a large number of genes has
been identified, the expected functional matching is still
missing, as shown for the α1D-AR subtype in testicularcapsule. This confirms the well-known fact that genes,
whose nature or correlation with a function is still un-
known, are present.
CONCLUSIONS
Our main objective was to use a phenotype-driven ap-
proach, which analyzes phenotypes from a dynamic
point of view, based on changes on the function of re-
ceptors induced by naturally occurring variants (hyper-
tension, aging, neurodegenerative diseases) or by surgi-
cal procedures (castration, denervation, transplantation,
removal of epithelium), as a tool to identify and charac-
terize genes for the phenotype without prior knowledge
of the underlying molecular mechanism or function. One
of the main and still unanswered questions is whether or
not these changes occur simultaneously with modifica-
tions of the corresponding genes.
Some interesting challenges were described when
functional and genomic data were analized toghether in
our lab, on the grounds of functionomics, as described
above. The most interesting result is the finding that
both α1A- and α1B- adrenoceptors were detected throughboth types of approach, while the presence of mRNA
for α1D-AR subtype was not shown by RT-PCR, in spiteof the demonstration of this subtype on contraction ex-
periments. This is an initial outcomming on functio-
nomics clearly showing, as expected, that a given gene
might have different independent functions in a very
same preparation or system. A similar partial lack of
correlation between function and genomics was also de-
scribed for adrenoceptors in rat seminal vesicle (Silva
et al. 1999). This approach also opens new possibili-
ties for other studies attempting to verify how the el-
ements of a given receptor cascade are related to one
or more genes.
Genomic influence is clearly present in many of
the sites of the receptor system cascade, especially with
reference to recent data about the relationship between
genes and receptors (Alexander et al. 2008), and ion
channels (Catterall et al. 2002). However, these stud-
ies have not yet taken full advantage of the many func-
tional quantitative results obtained in the last years in
order to construct more elaborated general models for
functionomics. Similarly, many of the functional results
cannot yet be explained by applying the principles of
molecular or cell biology, nor by looking for the corre-
sponding genes. It is clear that the crucial integrated in-
formation resides neither in the genome databases alone,
nor in the individual proteins coded by the genes, but
depends on knowing the black box in which the ex-
tent of protein interactions with cells, tissues, organs
and systems are also at hand. One has to agree that
applications and the potential of functionomics are at
the moment invigorating (Noble 2002). The present cli-
mate faces several challenges for those attempting to
perform funtionomic research, namely to explore func-
tionality in a quantitative manner all the way from the
level of the gene to that of the cell, and to the physio-
pharmacologycal functions of whole organs plus modu-
lation and regulatory systems, according to the expecta-
tions for the postgenomic era.
RESUMO
O termo funcionômica (Amin 2003, Neumann et al. 2004)
refere-se a um estudo posgenômico de Biologia de Sistemas
(Attur et al. 2002), usando um enfoque multidimensional, dinâ-
mico e simultâneo para células, tecidos e órgãos. Considera o
envolvimento presente e futuro da genômica, proteômica e
metabolômica incluindo os principais fatores que causam a
resposta biológica final e sua modulação em diferentes con-
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dições. Nosso objetivo na presente revisão é resumir o nosso
conhecimento atual em relação à funcionômica da farmacolo-
gia da musculatura lisa, baseada em resultados que obtivemos
ainda na era pregenômica, durante vários anos em nosso labo-
ratório. O presente enfoque baseia-se no que sabemos hoje em
dia sobre a dinâmica do sistema receptor, que compreende uma
cascata de fenômenos, que vão desde a administração de uma
droga até a resposta biológica. Descreveremos várias condi-
ções nas quais a resposta é modificada, com base em pertur-
bações produzidas na absorção, distribuição e metabolismo de
fármacos, interação com receptores, mobilização de segundos
mensageiros, bem como interações com um segundo sistema
receptor. Discutiremos também o papel da genômica e as inú-
meras falhas que devem ser preenchidas, para que se chegue
a um conhecimento integrado e cada vez melhor dos sistemas
receptores na musculatura lisa e para encurtar a ponte entre as
funções do sistema biológico, genômica e outras áreas recen-
temente introduzidas.
Palavras-chave: funcionômica, receptor, musculatura lisa,
genômica.
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